<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3196">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939301</url>
  </required_header>
  <id_info>
    <org_study_id>Kline-1UM NO for PE</org_study_id>
    <secondary_id>1UM1HL113203-01A1</secondary_id>
    <nct_id>NCT01939301</nct_id>
  </id_info>
  <brief_title>Nitric Oxide to Treat Pulmonary Embolism</brief_title>
  <official_title>Randomized Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind study to treat subjects diagnosed with pulmonary embolism
      with inhaled nitrix oxide. In this clinical trial investigators will randomized patients to
      receive inhaled nitric oxide or sham (oxygen only) for 24 hours. Patients must have a
      submassive pulmonary embolism (PE) and evidence of right ventricular (RV) heart dysfunction.
      Investigators hypothesize that the administration of inhaled NO + oxygen to patients with
      severe submassive PE will improve RV function, reduce RV strain and necrosis and improve
      dyspnea (difficulty breathing) more than sham oxygen treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>RV function and viability</measure>
    <time_frame>5 days or hospital discharge (whichever occurs first)</time_frame>
    <safety_issue>No</safety_issue>
    <description>RV function and viability assessed by the composite of normal RV size (&lt;42 mm in diastole) and TAPSE &gt; 16 mm and RIMP &gt; 0.40(echocardiograph systolic measurements for RV) and serum hsTnT &lt; 14pg/mL.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled nitric oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>oxygen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide</intervention_name>
    <arm_group_label>Inhaled Nitric Oxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18

          -  CTPA - proven PE, as interpreted by local radiologist

          -  At least one predictor of RV dysfunction:

               1. echocardiography with RV dilation or hypokinesis,

               2. estimated RVSP &gt;40mm HG,

               3. RV&gt;LV on CTPA,

               4. elevated troponin I (&gt;0.1 ng/mL) or natriuretic peptide (BNP &gt; 90 pg/mL),

               5. screening bedside cardiac ultrasound with color flow capability that shows RV
                  dysfunction,

               6. RV strain on ECG

          -  Plan by clinical care team to not use fibrinolytics or catheter or surgical
             embolectomy,

          -  Plan to admit to a bed with telemetry capability

        Exclusion Criteria:

          -  Vasopressor support

          -  Pregnancy

          -  Plan by clinical care team to use lytic or surgical embolectomy

          -  Plan by clinical team to use platelet inhibiting drugs

          -  Contraindication to anticoagulation

          -  Altered mental status such that the patient is unable to provide informed consent

          -  Inability to use a nasal cannula or face mask

          -  Comfort care measures instituted

          -  Supplemental oxygen requirements greater than can be administered via nasal cannula
             in order to maintain Sa)2 &gt; 80%

          -  Pneumothorax with decompression

          -  Serum MetHb &gt; 10%

          -  Recent use of drugs known to increase cGMP

          -  Use of nitroprusside or nitroglycerin within the last 4 hours

          -  Use of any other nitrates with in the past 24 hours

          -  Use of a fibrinolytic medicine within the past 14 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff A Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey A Kline, MD</last_name>
    <phone>317-287-3007</phone>
    <email>jefkline@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terry A Barclay, RN</last_name>
    <phone>317-630-2543</phone>
    <email>tbarclay@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeff A Kline, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>August 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Terry Barclay</investigator_full_name>
    <investigator_title>Research Project Manager</investigator_title>
  </responsible_party>
  <keyword>Pulmonary embolism clot</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
